OFIX — Orthofix Medical Inc.

Orthofix Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Global Net Sales: $218.6 million, a 3% increase year-over-year.
• Bone Growth Therapies (BGT): $68.3 million in Q4, up 7%, significantly outperforming the market.
• U.S. Limb Reconstruction: $38 million in Q4, with 8% growth.
• Global Spine Fixation: 10% growth in Q4, with U.S. sales up 5%.
• Adjusted EBITDA: $29.2 million, representing 13.4% of net sales, with a year-over-year margin expansion of approximately 230 basis points.
• Free Cash Flow: $16.8 million in Q4; nearly breakeven for the full year 2025.
• Cash Position: Ended Q4 with $85.1 million in total cash.

2. Strategic Updates and Business Highlights

• Spine Optimization: Successful transition of the Spine commercial channel, with 75% of U.S. net sales driven by the top 30 distributors.
• Product Launches: Anticipation for the full market release of the VIRATA Spinal Fixation System in the second half of 2026, expected to enhance surgical efficiency and drive growth.
• Limb Reconstruction Rebranding: Focused on four high-value clinical categories, targeting a $2.6 billion market opportunity.
• 7D FLASH Navigation: Continued strong performance, with a 30% increase in placements and significant utilization from earnout customers.

3. Forward Guidance and Outlook

• 2026 Net Sales Guidance: Expected between $850 million and $860 million, implying a year-over-year growth of approximately 5.5%.
• Adjusted EBITDA Guidance: Projected between $95 million and $98 million.
• Gross Margin Expectation: Approximately 72.5% for 2026, with continued focus on productivity improvements.
• Long-Range Plan Update: Extended timeline to 2028 for achieving 6.5% to 7.5% CAGR in net sales, reflecting the need for more time to realize benefits from the Spine channel optimization.

4. Bad News, Challenges, or Points of Concern

• Distributor Transition Pressure: The transition created temporary sales pressure, although performance improved towards the end of Q4.
• Legal Settlements: Potential legal settlements could impact free cash flow, with an accrual made in Q3.
• Biologics Performance: Experienced a decline due to distributor transitions; however, efforts are underway to revitalize this segment.
• Tariff Impact: Anticipated $1 million to $2 million impact in 2026, slightly higher than in 2025.

5. Notable Q&A Insights

• CMS Impact on BGT: Clarified that the CMS program will have a 1% headwind on BGT revenue in Q1 2026, but is considered immaterial for the year overall.
• Long-Term Revenue Targets: Confidence remains in achieving 6.5% to 7.5% CAGR despite extending the timeline, with emphasis on new product launches and channel optimization.
• Free Cash Flow Projections: Expected improvement in free cash flow for 2026, excluding legal settlements, with estimates suggesting an increase of $7 million to $8 million over 2025.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable concerns discussed during the earnings call, providing a comprehensive overview of Orthofix's performance and outlook.